[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-standardized-cutaneous-wounds-punch-biopsy-wounds\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-standardized-cutaneous-wounds-punch-biopsy-wounds":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100626588","phase-2-topical-ghk-cu-gel-for-acute-skin-wound-healing-100626588",false,"NCT07437586","Topical GHK-Cu Gel for Acute Skin Wound Healing","A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults","CuHeal","Inclusion Criteria:\n\n* Age 18 to 55 years at screening.\n* Healthy adult as determined by medical history and limited physical examination.\n* Body mass index (BMI) 18.0 to 30.0 kg\u002Fm².\n* Willing and able to comply with study visits and daily product application for 14 days.\n* Willing to avoid applying non-study topical products (including medicated creams, retinoids, acids) to the wound area during the study period.\n* For participants of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception through Day 21.\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to copper, peptides, gel excipients, adhesives, or dressings used in the study.\n* History of abnormal wound healing, hypertrophic scarring, or keloid formation.\n* Clinically significant dermatologic disease near the intended wound site (e.g., eczema, psoriasis, active infection).\n* Diabetes mellitus, peripheral vascular disease, immunodeficiency, or other condition that may impair wound healing (investigator judgment).\n* Use of systemic corticosteroids, immunosuppressants, or cytotoxic medications within 30 days prior to Day 0.\n* Current smoker or nicotine use (including vaping) within the past 3 months.\n* Pregnant or breastfeeding.\n* Participation in another interventional clinical study within 30 days prior to screening.\n* Any condition that, in the investigator's opinion, would make participation unsafe or could interfere with study assessments.",true,"ALL","18 Years","55 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel.\n\nParticipants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.",[29],"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)",[31,32,33,34,35,36,37,38],"GHK-Cu","copper peptide","Copper(II)-peptide complex","copper tripeptide-1","wound healing","re-epithelialization","skin repair","scar quality","RECRUITING","2026-02-22",{"date":42,"type":43},"2026-02-27","ACTUAL",{"date":45,"type":43},"2026-02-02",{"date":47,"type":23},"2028-03-17",{"name":49,"class":50},"Hudson Biotech","INDUSTRY"]